EMA’s CHMP recommends approval for AstraZeneca’s Saphnelo to treat SLE
A fully human monoclonal antibody, Saphnelo targets subunit 1 of the type one interferon (type 1 IFN) receptor, blocking the type 1 IFN’s activity. It has been recommended
A once-weekly long-acting recombinant human growth hormone, somatrogon is intended for treating children from three years of age and adolescents experiencing growth disturbance because of inadequate secretion of
An interleukin-23 (IL-23) inhibitor, Risankizumab is intended to treat patients with Crohn’s disease who have shown insufficient response, lost response or are intolerant to biologic or conventional treatment.